

Global Ovarian Cancer Drugs Market Size study, by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), Treatment, End-use, and Regional Forecasts 2022-2032

<https://marketpublishers.com/r/G62A8C2DAA4FEN.html>

Date: May 2025

Pages: 285

Price: US\$ 3,218.00 (Single User License)

ID: G62A8C2DAA4FEN

Abstracts

The Global Ovarian Cancer Drugs Market is valued at approximately USD 3.59 billion in 2023 and is anticipated to grow with a robust CAGR of more than 6.60% over the forecast period 2024-2032. Ovarian cancer, often diagnosed in later stages due to its subtle symptomatology, remains one of the deadliest gynecological malignancies. In recent years, however, the therapeutic landscape has undergone a transformative shift fueled by innovations in targeted therapies and immuno-oncology. The advent of PARP inhibitors, angiogenesis blockers, and PD-L1 checkpoint inhibitors has dramatically elevated survival rates and recurrence control, offering patients highly personalized and more effective treatment options. As a result, the global ovarian cancer drugs market is rapidly evolving from conventional chemotherapy dominance toward precision-based combination regimens.

This market's upward momentum is anchored by an amalgam of contributing factors—ranging from increasing global cancer burden and rising awareness programs to improvements in diagnostic capabilities and biomarker screening. The strategic integration of next-generation sequencing (NGS) in clinical workflows has not only enhanced the detection of BRCA mutations but has also broadened the eligible patient pool for PARP-based therapies. Meanwhile, major pharmaceutical companies are leveraging these advancements by intensifying R&D pipelines, forming clinical collaborations, and accelerating regulatory submissions for novel molecules. However, cost-containment pressures, limited healthcare access in low-income economies, and side effects associated with long-term targeted therapy usage present noteworthy challenges that could temper market expansion.

Pharmaceutical giants are also aggressively adopting lifecycle management strategies such as label expansions and combination trial rollouts, thereby reinforcing their competitive moat. One of the major paradigm shifts includes the application of real-world data to monitor drug effectiveness and guide value-based pricing mechanisms, especially in advanced economies. Additionally, biosimilars and generics for legacy chemotherapeutics continue to infiltrate cost-sensitive markets, balancing innovation with accessibility. The confluence of digital therapeutics, AI-based treatment planning, and patient-centric care models is steadily paving the way for personalized oncology solutions, strengthening treatment outcomes and fostering greater market penetration.

Geographically, North America dominates the ovarian cancer drugs market due to its sophisticated healthcare infrastructure, early adoption of targeted therapies, and extensive clinical trial activity. The U.S. remains a research hotspot, supported by government-funded initiatives and an evolving reimbursement ecosystem. Europe follows suit, propelled by favorable drug approvals and comprehensive oncology care systems across countries like Germany, France, and the UK. Meanwhile, Asia Pacific is emerging as a high-potential growth frontier with rising cancer incidence, improving healthcare accessibility, and increasing investments in biologics manufacturing. Countries such as China and India are proactively adopting advanced oncology protocols, supported by public-private funding and regulatory modernization, which are likely to boost regional growth substantially through 2032.

Major market player included in this report are:

GlaxoSmithKline plc

F. Hoffmann-La Roche Ltd.

Pfizer Inc.

AstraZeneca

Merck & Co., Inc.

Clovis Oncology

AbbVie Inc.

Amgen Inc.

Genentech, Inc.

Johnson & Johnson

Tesaro Inc. (a GSK Company)

Mylan N.V.

Bristol-Myers Squibb Company

ImmunoGen, Inc.

Novartis AG

The detailed segments and sub-segment of the market are explained below:

By Therapeutic Class

PARP Inhibitors

PD-L1 Inhibitors

Angiogenesis Inhibitors

By Treatment

Chemotherapy

Targeted Therapy

Immunotherapy

Others

By End-use

Hospitals

Cancer Treatment Centers

Research Institutes

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

Rest of Europe

Asia Pacific

China

India

Japan

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East & Africa

Saudi Arabia

South Africa

Rest of Middle East & Africa

Years considered for the study are as follows:

Historical year – 2022

Base year – 2023

Forecast period – 2024 to 2032

Key Takeaways:

Global Ovarian Cancer Drugs Market Size study, by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), Tr...

Market Estimates & Forecast for 10 years from 2022 to 2032.

Annualized revenues and regional level analysis for each market segment.

Detailed analysis of geographical landscape with Country level analysis of major regions.

Competitive landscape with information on major players in the market.

Analysis of key business strategies and recommendations on future market approach.

Analysis of competitive structure of the market.

Demand side and supply side analysis of the market.

Contents

CHAPTER 1. GLOBAL OVARIAN CANCER DRUGS MARKET EXECUTIVE SUMMARY

- 1.1. Global Ovarian Cancer Drugs Market Size & Forecast (2022–2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
 - 1.3.1. By Therapeutic Class
 - 1.3.2. By Treatment
 - 1.3.3. By End-use
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion

CHAPTER 2. GLOBAL OVARIAN CANCER DRUGS MARKET DEFINITION AND RESEARCH ASSUMPTIONS

- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
 - 2.3.1. Inclusion & Exclusion
 - 2.3.2. Limitations
 - 2.3.3. Supply Side Analysis
 - 2.3.3.1. Availability
 - 2.3.3.2. Infrastructure
 - 2.3.3.3. Regulatory Environment
 - 2.3.3.4. Market Competition
 - 2.3.3.5. Economic Viability (Consumer's Perspective)
 - 2.3.4. Demand Side Analysis
 - 2.3.4.1. Regulatory Frameworks
 - 2.3.4.2. Technological Advancements
 - 2.3.4.3. Environmental Considerations
 - 2.3.4.4. Patient Awareness & Screening Practices
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates

CHAPTER 3. GLOBAL OVARIAN CANCER DRUGS MARKET DYNAMICS

Global Ovarian Cancer Drugs Market Size study, by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), Tr...

3.1. Market Drivers

- 3.1.1. Rising Incidence and Late-Stage Diagnosis Rates
- 3.1.2. Breakthroughs in Targeted and Immuno-Oncology Therapies
- 3.1.3. Expansion of Genetic Screening and Biomarker Identification

3.2. Market Challenges

- 3.2.1. High Cost of Novel Biologics and Patient Affordability
- 3.2.2. Limited Access to Advanced Treatments in Emerging Economies
- 3.2.3. Management of Therapy-Related Adverse Events

3.3. Market Opportunities

- 3.3.1. Development of Combination Regimens and Personalized Protocols
- 3.3.2. Orphan Drug Incentives and Fast-Track Regulatory Pathways
- 3.3.3. Expansion of Maintenance Therapy Post-Remission

CHAPTER 4. GLOBAL OVARIAN CANCER DRUGS MARKET INDUSTRY ANALYSIS

4.1. Porter's 5 Force Model

- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's 5 Force Model
- 4.1.7. Porter's 5 Force Impact Analysis

4.2. PESTEL Analysis

- 4.2.1. Political
- 4.2.2. Economical
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal

4.3. Top Investment Opportunity

4.4. Top Winning Strategies

4.5. Disruptive Trends

4.6. Industry Expert Perspective

4.7. Analyst Recommendation & Conclusion

CHAPTER 5. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE & FORECASTS

BY THERAPEUTIC CLASS 2022–2032

5.1. Segment Dashboard

5.2. Ovarian Cancer Drugs Market: Therapeutic Class Revenue Trend Analysis, 2022 & 2032 (USD Billion)

5.2.1. PARP Inhibitors

5.2.2. PD-L1 Inhibitors

5.2.3. Angiogenesis Inhibitors

CHAPTER 6. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE & FORECASTS BY TREATMENT 2022–2032

6.1. Segment Dashboard

6.2. Ovarian Cancer Drugs Market: Treatment Revenue Trend Analysis, 2022 & 2032 (USD Billion)

6.2.1. Chemotherapy

6.2.2. Targeted Therapy

6.2.3. Immunotherapy

6.2.4. Others

CHAPTER 7. GLOBAL OVARIAN CANCER DRUGS MARKET SIZE & FORECASTS BY REGION 2022–2032

7.1. North America Market

7.1.1. U.S. Market

7.1.1.1. Therapeutic Class Breakdown Size & Forecasts, 2022–2032

7.1.1.2. Treatment Breakdown Size & Forecasts, 2022–2032

7.1.2. Canada Market

7.2. Europe Market

7.2.1. UK Market

7.2.2. Germany Market

7.2.3. France Market

7.2.4. Spain Market

7.2.5. Italy Market

7.2.6. Rest of Europe Market

7.3. Asia Pacific Market

7.3.1. China Market

7.3.2. India Market

7.3.3. Japan Market

- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
 - 7.4.1. Brazil Market
 - 7.4.2. Mexico Market
 - 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
 - 7.5.1. Saudi Arabia Market
 - 7.5.2. South Africa Market
 - 7.5.3. Rest of Middle East & Africa Market

CHAPTER 8. COMPETITIVE INTELLIGENCE

- 8.1. Key Company SWOT Analysis
 - 8.1.1. GlaxoSmithKline plc
 - 8.1.2. F. Hoffmann-La Roche Ltd.
 - 8.1.3. Pfizer Inc.
- 8.2. Top Market Strategies
- 8.3. Company Profiles
 - 8.3.1. GlaxoSmithKline plc
 - 8.3.1.1. Key Information
 - 8.3.1.2. Overview
 - 8.3.1.3. Financial (Subject to Data Availability)
 - 8.3.1.4. Product Summary
 - 8.3.1.5. Market Strategies
 - 8.3.2. F. Hoffmann-La Roche Ltd.
 - 8.3.3. Pfizer Inc.
 - 8.3.4. AstraZeneca
 - 8.3.5. Merck & Co., Inc.
 - 8.3.6. Clovis Oncology
 - 8.3.7. AbbVie Inc.
 - 8.3.8. Amgen Inc.
 - 8.3.9. Genentech, Inc.
 - 8.3.10. Johnson & Johnson
 - 8.3.11. Tesaro Inc. (a GSK Company)
 - 8.3.12. Mylan N.V.
 - 8.3.13. Bristol-Myers Squibb Company
 - 8.3.14. ImmunoGen, Inc.

8.3.15. Novartis AG

CHAPTER 9. RESEARCH PROCESS

9.1. Research Process

9.1.1. Data Mining

9.1.2. Analysis

9.1.3. Market Estimation

9.1.4. Validation

9.1.5. Publishing

9.2. Research Attributes

I would like to order

Product name: Global Ovarian Cancer Drugs Market Size study, by Therapeutic Class (PARP, PD-L1, Angiogenesis Inhibitors), Treatment, End-use, and Regional Forecasts 2022-2032

Product link: <https://marketpublishers.com/r/G62A8C2DAA4FEN.html>

Price: US\$ 3,218.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G62A8C2DAA4FEN.html>